News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2014

Epigenomics AG: Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening

Epigenomics AG / Key word(s): Scientific publication 27.10.2014 / 08:30 Results of Adherence Study Published in BMC Gastroenterology Demonstrate that Epigenomics’ Blood-based Epi proColon(R) Improves Compliance to CRC Screening Berlin (Germany) and Germantown, MD (U.S.A), October 27, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced […]

Read more

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics raises USD 5.3 million from its strategic commercialization partner BioChain

Epigenomics AG / Key word(s): Capital Increase/Miscellaneous 16.10.2014 09:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. ————————————————————————— Berlin (Germany) and Germantown (USA), October 16, 2014 – Epigenomics AG (ISIN: DE000A11QW50, […]

Read more

Epigenomics AG: Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain

Epigenomics AG / Key word(s): Capital Increase 16.10.2014 / 09:30 Epigenomics AG raises USD 5.3 million from its strategic commercialization partner BioChain Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), October 16, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company […]

Read more

Epigenomics AG: Epigenomics Provides Corporate Update

Epigenomics AG / Key word(s): Miscellaneous 01.10.2014 / 14:00 Epigenomics Provides Corporate Update Berlin (Germany) and Germantown, MD (U.S.A.), October 1, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today provides a corporate update on major developments. Epigenomics, in consultations with the U.S. Food and Drug Administration […]

Read more

Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG mit dem Ziel der europaweiten Verbreitung

Epigenomics AG / Veröffentlichung der Gesamtzahl der Stimmrechte 30.09.2014 11:55 Veröffentlichung der Gesamtzahl der Stimmrechte nach § 26a WpHG, übermittelt durch DGAP – ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. ————————————————————————— Hiermit teilt die Epigenomics AG mit, dass die Gesamtzahl der Stimmrechte am Ende des Monats September […]

Read more

Epigenomics AG: Epigenomics AG converts to registered shares

Epigenomics AG / Key word(s): Miscellaneous 19.09.2014 / 15:51 Berlin (Germany), Germantown, MD (U.S.A.), September 19, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, will convert its 13,510,892 bearer shares into registered shares effective Monday, September 22, 2014 at a ratio of 1:1. The conversion, which was […]

Read more